Muñoz N, Bosch F X, de Sanjosé S, Tafur L, Izarzugaza I, Gili M, Viladiu P, Navarro C, Martos C, Ascunce N
Unit of Field and Intervention Studies, International Agency for Research on Cancer, Lyon, France.
Int J Cancer. 1992 Nov 11;52(5):743-9. doi: 10.1002/ijc.2910520513.
To evaluate the association between human papillomavirus (HPV) and cervical cancer, we performed a population-based case-control study in Columbia and Spain, the former country having an incidence rate of cervical cancer about 8 times higher than the latter. It included 436 cases of histologically confirmed invasive cervical cancer and 387 randomly selected population controls. Information on demographic variables, sexual behaviour and other risk factors was obtained by interview. HPV-DNA was measured in cervical-swab specimens with 3 hybridization assays: ViraPap, Southern hybridization (SH) and polymerase chain reaction (PCR). The presence of HPV-DNA and detection of types 16, 18, 31, 33 and 35 were strongly associated with cervical cancer in each country regardless of the assay used. For both countries combined the adjusted odds ratios and 95% confidence intervals were: ViraPap OR = 25.9 (10.0-66.7); SH OR = 6.8 (3.4-13.4); and PCR OR = 28.8 (15.7-52.6). HPV-16 was the most common type detected in both cases and controls. Our results indicate that there is a very strong association between HPV 16, 18, 31, 33 and 35 and invasive cervical cancer and that this association is probably causal.
为评估人乳头瘤病毒(HPV)与宫颈癌之间的关联,我们在哥伦比亚和西班牙开展了一项基于人群的病例对照研究,前者宫颈癌发病率约为后者的8倍。该研究纳入了436例经组织学确诊的浸润性宫颈癌病例和387例随机选取的人群对照。通过访谈获取了人口统计学变量、性行为及其他风险因素的信息。采用3种杂交检测法检测宫颈拭子标本中的HPV-DNA:ViraPap法、Southern杂交(SH)法和聚合酶链反应(PCR)法。无论采用哪种检测法,HPV-DNA的存在以及16、18、31、33和35型的检测在每个国家均与宫颈癌密切相关。对于两个国家的数据合并分析,校正后的比值比及95%置信区间为:ViraPap法OR = 25.9(10.0 - 66.7);SH法OR = 6.8(3.4 - 13.4);PCR法OR = 28.8(15.7 - 52.6)。HPV-16是在病例组和对照组中检测到的最常见类型。我们的结果表明,HPV 16、18、31、33和35与浸润性宫颈癌之间存在非常强的关联,且这种关联可能具有因果关系。